iTeos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

iTeos Therapeutics CEO'su Michel Detheux, Aug2011 tarihinde atandı, in görev süresi 13.25 yıldır. in toplam yıllık tazminatı $ 5.77M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10% maaş ve 90% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.058% ine doğrudan sahiptir ve bu hisseler $ 187.33K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 4.7 yıldır.

Anahtar bilgiler

Michel Detheux

İcra Kurulu Başkanı

US$5.8m

Toplam tazminat

CEO maaş yüzdesi	10.0%
CEO görev süresi	13.3yrs
CEO sahipliği	0.06%
Yönetim ortalama görev süresi	4.4yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16

iTeos Therapeutics EPS misses by $0.11

Nov 12

CEO Tazminat Analizi

Michel Detheux'un ücretlendirmesi iTeos Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$135m
Dec 31 2023	US$6m	US$579k	-US$113m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	US$12m
Dec 31 2022	US$11m	US$556k	US$97m
Sep 30 2022	n/a	n/a	US$261m
Jun 30 2022	n/a	n/a	US$330m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$6m	US$525k	US$215m
Sep 30 2021	n/a	n/a	US$15m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$17m	US$463k	-US$43m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$2m	US$460k	-US$27m

Tazminat ve Piyasa: Michel 'nin toplam tazminatı ($USD 5.77M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Michel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Michel Detheux (57 yo)

13.3yrs

Görev süresi

US$5,767,774

Tazminat

Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michel Detheux	President	13.3yrs	US$5.77m	0.058% $ 187.3k
Matthew Gall	Chief Financial Officer	4.4yrs	US$2.72m	0.053% $ 171.2k
Matthew Call	Chief Operating Officer	5.3yrs	US$2.80m	0.26% $ 827.2k
Yvonne McGrath	Chief Scientific Officer	2.8yrs	Veri yok	Veri yok
Adi Osovsky	Executive Vice President of Legal	1.8yrs	Veri yok	Veri yok
Philippe Brantegem	Executive Vice President of Human Resources	4.8yrs	Veri yok	Veri yok
David Feltquate	Chief Medical Officer	less than a year	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: ITOS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michel Detheux	President	12.8yrs	US$5.77m	0.058% $ 187.3k
Ann Rhoads	Independent Director	4.4yrs	US$317.52k	0% $ 0
David Hallal	Independent Chairman of the Board	6.4yrs	US$416.42k	0% $ 0
Aaron Davis	Independent Director	4.7yrs	US$253.52k	0% $ 0
Timothy Van Hauwermeiren	Independent Director	6.4yrs	US$303.52k	0% $ 0
Matthew Vander Heiden	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Tony W. Ho	Independent Director	3.6yrs	US$305.02k	0% $ 0
Robert Iannone	Independent Director	3.6yrs	US$308.27k	0% $ 0
Gordon Freeman	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Benoit Van den Eynde	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Florent Ginhoux	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roberta Zappasodi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ITOS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

iTeos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

iTeos Therapeutics, Inc. Appoints David Feltquate as Chief Medical Officer

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

Iteos Therapeutics, Inc. Announces Board Changes

Chief Operating Officer exercised options to buy US$531k worth of stock.

Recent updates

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics, Inc. Appoints David Feltquate as Chief Medical Officer

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2000 Value-Defensive Index

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

New minor risk - Shareholder dilution

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

New major risk - Revenue size

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024

Iteos Therapeutics, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.90 loss per share (vs US$0.028 profit in 3Q 2022)

New minor risk - Share price stability

Price target decreased by 11% to US$35.75

Second quarter 2023 earnings released: US$0.96 loss per share (vs US$0.16 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Consensus revenue estimates increase by 46%

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Price target decreased by 8.9% to US$40.27

Chief Operating Officer exercised options to buy US$531k worth of stock.

Investor sentiment deteriorates as stock falls 17%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

High number of new directors

iTeos Therapeutics, Inc. Announces Resignation of Matthew Roden from the Board

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

High number of new directors

Consensus revenue estimates fall by 23%

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

iTeos Therapeutics: Too Many Unknowns

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Chairman of the Board notifies of intention to sell stock

Investor sentiment improved over the past week

High number of new directors

Price target decreased to US$46.20

Investor sentiment deteriorated over the past week

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Consensus revenue estimates increase by 30%

Price target increased to US$50.20

President notifies of intention to sell stock

iTeos Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

President exercised options and sold US$318k worth of stock

Price target increased to US$50.20

Consensus revenue estimates fall by 29%

Chief Medical Officer exercised options and sold US$111k worth of stock

Chief Scientific Officer exercised options and sold US$325k worth of stock

Chief Medical Officer exercised options and sold US$110k worth of stock

President notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$123k worth of stock

Chief Medical Officer exercised options and sold US$333k worth of stock

Chief Financial Officer recently sold US$232k worth of stock

Price target increased to US$50.00

Chief Medical Officer exercised options and sold US$106k worth of stock

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Chief Medical Officer exercised options and sold US$846k worth of stock

President notifies of intention to sell stock

Chief Financial Officer exercised options to buy US$381k worth of stock.

President notifies of intention to sell stock